Repare Therapeutics Sells Polθ ATPase Inhibitor to Gilead Sciences in a Multi-Million Dollar Deal
In a significant development, Repare Therapeutics, a clinical-stage precision oncology company, has agreed to sell its Polθ ATPase inhibitor, RP-3467, to Gilead Sciences for up to $30 million. This acquisition is a strategic move by Gilead to bolster its oncology research and development capabilities.
The Deal and Its Significance
Repare Therapeutics, based in Cambridge, Massachusetts, and Montreal, announced the definitive asset purchase agreement, marking a substantial portfolio transaction for the company. The agreement highlights the potential of RP-3467, a highly potent small molecule inhibitor, as a best-in-class Polθ ATPase inhibitor.
The terms of the deal include a $25 million upfront payment and an additional $5 million upon the completion of specified technology transfer activities. This acquisition is the third and most significant portfolio transaction for Repare this year, as stated by Steve Forte, the company's President, CEO, and CFO.
Impact on Repare's Shareholders
In a separate development, Repare also entered into an arrangement agreement with XenoTherapeutics and Xeno Acquisition Corp. (collectively, "Xeno") on November 14, 2025. Under this agreement, Xeno will acquire all of Repare's issued and outstanding common shares. Repare shareholders will receive a cash payment per share based on the company's cash balance at the closing of the arrangement transaction, after deducting transaction costs and outstanding liabilities.
The upfront payment from Gilead has increased Repare's cash balance, leading to a higher estimated cash payment for shareholders, now estimated at approximately US$2.20 per common share.
RP-3467: A Promising Therapeutic Candidate
RP-3467 is a promising synthetic lethality target associated with BRCA mutations and other genomic alterations. It is currently being evaluated in the POLAR Phase 1 clinical trial for its safety, pharmacokinetics, pharmacodynamics, and preliminary activity in various advanced cancers, including ovarian, breast, prostate, and pancreatic cancers.
About Repare Therapeutics
Repare Therapeutics is a clinical-stage company specializing in precision oncology. Their proprietary synthetic lethality approach enables the discovery and development of novel therapeutics, particularly highly targeted cancer therapies focused on genomic instability and DNA damage repair.
Additional Information and Resources
Shareholders can access the definitive proxy statement on Schedule 14A and other relevant documents regarding the proposed transactions with Gilead and Xeno. These documents provide crucial information about the transactions and related matters, including a special meeting of shareholders scheduled for January 16, 2026, to seek approvals for the transactions.
Investors and security holders are advised to review these documents, available on the SEC's website or through Repare's Investor Relations. The proxy statement contains details about the participants in the solicitation of proxies from the company's shareholders and their interests in the transactions.
Looking Ahead: Opportunities and Challenges
The transactions with Gilead and Xeno present exciting opportunities for Repare Therapeutics, but they also come with potential risks and uncertainties. These include the challenges of clinical development, regulatory approvals, and market dynamics. The company's ability to navigate these factors will be crucial in determining the success of these strategic moves.
But here's where it gets controversial: How might this acquisition impact the broader landscape of precision oncology? Could it lead to more targeted therapies for patients with specific genomic alterations? Or might it raise concerns about accessibility and affordability of such treatments? Share your thoughts in the comments below, and let's explore the potential implications together.
